Theratechnologies EBITDA
Cos'è EBITDA di Theratechnologies?
EBITDA di Theratechnologies, Inc. è -$22.62
Qual è la definizione di EBITDA?
L'EBITDA è il reddito di una società prima di interessi, imposte, deprezzamenti e ammortamenti ed è una misura contabile calcolata utilizzando gli utili netti di una società, prima che vengano sottratti interessi passivi, imposte, ammortamenti e ammortamenti come proxy della redditività corrente di un'azienda.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA di aziende nel Health Care settore su TSX rispetto a Theratechnologies
Cosa fa Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Aziende con ebitda simili a Theratechnologies
- Jaykay Enterprises ha EBITDA di -₨22.74
- Virnetx Corp ha EBITDA di -$22.74
- Hong Kong Finance Investment ha EBITDA di -HKD$22.73
- Dafeng Port Heshun Technology ha EBITDA di -HKD$22.70
- Green Organic Dutchman ha EBITDA di -CAD$22.69
- PyroGenesis Canada ha EBITDA di -CAD$22.68
- Theratechnologies ha EBITDA di -$22.62
- Winfull ha EBITDA di -HKD$22.62
- Honworld ha EBITDA di -¥22.61
- Asia-Pac Investment ha EBITDA di -HKD$22.60
- National Access Cannabis ha EBITDA di -CAD$22.58
- Ching Lee ha EBITDA di -HKD$22.54
- Axon Enterprise Inc ha EBITDA di -$22.53